Physician profile
Brian J So
NPI 1841499100
$28,310.78
in general payments reported to CMS, 2019-2025
40 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $1,403 · 2021: $2,212 · 2022: $8,557 · 2023: $9,997 · 2024: $2,409 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $6,760 · Travel and Lodging: $237 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $6,760.45 |
| Travel and Lodging | $237.11 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $14,726.35 | 2020-2023 | Gimoti |
| Abbvie INC. | $3,909.73 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,822.05 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,415.06 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,218.28 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $1,057.48 | 2019-2025 | |
| Gilead Sciences, INC. | $963.13 | 2019-2025 | |
| Genzyme Corporation | $454.70 | 2022-2025 | |
| Ardelyx, INC. | $438.82 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $292.84 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $230.80 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $191.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $174.94 | 2020-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $165.19 | 2021-2024 | Dificid |
| Braintree Laboratories, INC. | $139.02 | 2020-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $120.88 | 2019-2024 | Rebyota |
| Axonics, INC. | $93.36 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $92.23 | 2021-2023 | |
| Celgene Corporation | $89.43 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $82.16 | 2021 | |
| Ucb, INC. | $67.99 | 2019-2020 | |
| Allergan, INC. | $61.31 | 2019-2020 | |
| Alfasigma USA, INC. | $60.25 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $52.40 | 2023 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $47.56 | 2023-2024 | Imfinzi |
| Amgen INC. | $44.64 | 2020-2021 | |
| Mauna Kea Technologies, INC. | $39.43 | 2021-2024 | |
| Medtronic, INC. | $37.76 | 2021-2023 | Endoflip |
| Ironwood Pharmaceuticals, INC | $34.92 | 2019 | |
| Bioventus LLC | $29.44 | 2021 | |
| Daiichi Sankyo INC. | $28.08 | 2019-2020 | |
| Novo Nordisk INC | $20.61 | 2023 | Wegovy |
| Enterra Medical, INC. | $16.46 | 2023 | |
| Celltrion USA INC. | $15.14 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $14.85 | 2024 | Givlaari |
| Ipsen Biopharmaceuticals, INC | $14.84 | 2025 | Iqirvo |
| Ambu INC. | $13.92 | 2020 | |
| Shionogi INC | $13.75 | 2020 | |
| Organon LLC | $13.47 | 2023 | Hadlima, Renflexis |
| Echosens North America, INC. | $6.37 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian So listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.